Dear all,
The Third International Inflammatory Breast Cancer Conference will be held December 1,2 in Philadelphia at The Sofitel Hotel.
I have been helping an IBC patient of Dr. Massimo Cristofanilli and I just spoke to Dr. C. a view minutes ago. He think this will be an excellent conference. One important thing that will be discussed is the cutting edge work being done on the ALK mutation that seems to be present in a lot of IBC.
I will be presenting a short talk, about the TNBC Foundation, in the Advocacy Section Saturday night and will also be presenting a poster on TNBC Foundation and IBC on Sunday.
It seems that when women have IBC about 30-35% of the time it is also TNBC. It can be a very challenging combination to treat and after helping about ten women with IBC/TN over the last several years it has become a particular passion of mine. I am hoping that the efforts of the scientists present will help the women with IBC and IBC/TN. I know it is a small group, in numbers, and therefore challenging, funding-wise, but I so admire those who have dedicated their efforts to find a cure/better treatment for the IBC community.
Conferences like this are particularly interesting to me because, I believe, there are only about 200 participants expected so there is really a wonderful opportunity to interact with physicians, researchers. and fellow advocates. And it is a very focused conference. Next week I will be attending SABCS in San Antonio and I think there are about 8000 who will attend.
If anyone involved with IBC wants to come there is a $125 Advocacy rate compared to $450 for regular attendees and there is also a special $50 rate for the reception, only, on Saturday night.
Please let me know, in a PM, if you are planning to attend. I would love to say hello. I will give you my cell phone number and email and hopefully we can connect at the Conference.
warmly,
Steve
Here is the program
Saturday, December 1, 2012
1:00-5:00 pm REGISTRATION & POSTER SET-UP
5:00-5:30 pm OPENING
Session Chairs: Massimo Cristofanilli, MD and Kenneth van Golen, PhD
Margaret Foti, PhD, MD
American Association for Cancer Research
Frances M. Visco, JD
National Breast Cancer Coalition
Elaine Grobman
Philadelphia Affiliate of Susan G. Komen for the Cure
Senator Timothy Z. Jennings
New Mexico State Senate
5:30-6:30 pm PLENARY LECTURE: MYC AND CANCER: EVOLVING CONCEPTS IN TUMOR METABOLISM
Session Chairs: Massimo Cristofanilli, MD and Kenneth van Golen, PhD
Chi Van Dang, MD, PhD John H. Glick, MD Abramson Cancer Center Director’s Professor Director
Abramson Cancer Center of the University of Pennsylvania
6:30-7:30 pm SESSION EPIDEMIOLOGY OF IBC: NEW RISK FACTORS
Session Chairs: Melissa Bondy, PhD and Amr Soliman, MD, PhD
6:30-7:00 pm Current Epidemiologic Studies: Advances and Obstacles
Paul Levine, MD
The George Washington University School of Medicine
7:00-7:10 pm Q & A
7:30-8:30 am REGISTRATION, CONTINENTAL BREAKFAST & POSTER DISPLAY
8:30-10:30 am CONCURRENT SESSION 1: BREAKING NEWS: IBC RESEARCH UPDATE
Session Chair: Kenneth van Golen, PhD and Steven Van Laere, MSc, PhD
8:30-9:00 am New Concepts in the Biology and Therapy of Brain Metastases of Breast Cancer
Patricia S. Steeg, PhD
The National Cancer Institute
9:00-9:10 am Q & A
8:30-10:30 am CONCURRENT SESSION 2: NURSE, ALLIED HEALTH PROFESSIONAL & ADVOCATES EDUCATIONAL SESSION
Session Chairs: Bernadette Ciukurescu,BSN,RN-BC & Bonnie Miller,RN,BSN,OCN,FAAMA
8:30-9:45 am Inflammatory Breast Cancer: Past , Present and Future
Pam Alizadeh, RN, Onc NP, MS, AOCN, CBCN
The University of Texas MD Anderson Cancer Center
9:45-10:30 am PANEL DISCUSSION
Pam Alizadeh, RN, Onc NP, MS, AOCN, CBCN
The University of Texas MD Anderson Cancer Center
Valerie Fraser, IBC Survivor/Research Advocate and President
Michigan Breast Cancer Coalition
Jessie Schol, RN, BSN, OCN
Fox Chase Cancer Center
10:30-11:00 am BREAK & POSTER DISPLAY
11:00-1:00 pm SESSION 3: EVOLVING IBC TREATMENTS: FROM BENCH TO BEDSIDE
Session Chairs: Massimo Cristofanilli, MD and Patrice Viens, MD
11:00-11:30 am Evolving HER-2 Targeted Therapies in Breast Cancer: Lessons for IBC
Neil Spector, MD
Duke Cancer Institute
11:30-11:40 am Q & A
ABSTRACTS
11:40-11:55 am Response to neoadjuvant systemic therapy (NST) in inflammatory breast cancer (IBC) according to estrogen receptor (ER) and HER2 expression
Hiroko Masuda, MD, PhD
The University of Texas MD Anderson Cancer Center
11:55-12:00pm Q & A
Sunday, December 2, 2012 (Continuted)
12:00-12:15pm Epidemiological risk factors and normal breast tissue markers in inflammatory breast cancer
Rachel L. Atkinson, PhD
The University of Texas MD Anderson Cancer Center
12:15-12:20pm Q & A
12:20-12:35pm Implications of prevalence of anaplastic lymphoma kinase in inflammatory breast cancer
Fredika Robertson, PhD
The University of Texas MD Anderson Cancer Center
12:35-12:40pm Q & A
12:40-12:55pm Mutation discordance between tissue sources from the same patient
R. Katherine Alpaugh, PhD
Fox Chase Cancer Center
12:55-1:00pm Q & A
1:00-2:00 pm LUNCH & POSTER DISPLAY
2:00-3:00 pm SESSION 4: LOCOREGIONAL THERAPIES: UNANSWERED QUESTIONS
Session Chairs: Wendy Woodward, MD, PhD & Prof. Francois Bertucci, MD, PhD
2:00-2:30 pm Evolving Locoregional Radiation Therapy Modalities for IBC
Wendy Woodward, MD, PhD
The University of Texas MD Anderson Cancer Center
2:30-2:40 pm Q & A
Sunday, December 2, 2012 (Continuted)
ABSTRACTS
2:40-2:55 pm Assessment of residual disease using mammography (MG), sonography (US), and magnetic resonance imaging (MRI) in patients (pts) with inflammatory breast cancer (IBC) who received neoadjuvant chemotherapy (NAC)
H. Carisa Le-Petross, MD
The University of Texas MD Anderson Cancer Center
2:55-3:00 pm Q & A
3:00-3:30 pm BREAK & POSTER DISPLAY
3:30-4:30 pm SESSION 5: TISSUE LABORATORY AND IMAGING: DETECTION, DISCOVERY AND MONITORING
Session Chairs: Sanford H. Barsky, MD and Luc Y. Dirix, MD
3:30-4:00 pm Protein Micoarray: Molecular Dianostics for Discovery and Therapeutic Targeting
Emanuel F. Petricoin, PhD
George Mason University
4:00-4:10 pm Q & A
ABSTRACTS
4:10-4:25 pm CTC and CEC in IBC patients during neoadjuvant chemotherapy combine with bevacizumab and trastuzumab according to HER2+ status: Finding of the BEVERLY 01 & 02 trials
Francois-Clement Bidard, MD, PhD
Institut Curie
4:25-4:30 pm Q & A
4:30-6:00 pm ROUNDTABLE DISCUSSION: LESSONS LEARNED AND BEYOND
6:00-7:00 pm CLOSING